licensing Archives -

Trailing its RSV vaccine rivals, Bavarian Nordic cuts China deal

Phil Taylor Bavarian Nordic, GlaxoSmithKline, Johnson & Johnson, licensing, Moderna, Nuance Pharma, Pfizer, respiratory syncytial virus, vaccine 0 Comment

Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian

Trailing its RSV vaccine rivals, Bavarian Nordic cuts China deal

https://pharmaphorum.com/news/trailing-its-rsv-vaccine-rivals-bavarian-nordic-cuts-china-deal/

News/ News/ Oncology

Lilly revives ImmunoGen ADC pact with new $1.7bn deal

Phil Taylor antibody-drug conjugate, Eli Lilly, immunogen, licensing, Oncology, partnering 0 Comment

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come

Lilly revives ImmunoGen ADC pact with new $1.7bn deal

https://pharmaphorum.com/news/lilly-revives-immunogen-adc-pact-with-new-1-7bn-deal/

News

GSK aims at NASH target with $1bn-plus Arrowhead alliance

Phil Taylor Arrowhead Pharmaceuticals, GlaxoSmithKline, licensing, NASH, partnering 0 Comment

GlaxoSmithKline has joined the ranks of drugmakers trying to develop new drugs for non-alcoholic steatohepatitis (NASH) – a

GSK aims at NASH target with $1bn-plus Arrowhead alliance

https://pharmaphorum.com/news/gsk-aims-at-nash-target-with-1bn-plus-arrowhead-alliance/

News/ News/ R&D

Lilly taps Lycia for protein degrader tech in $1.6bn deal

Phil Taylor Eli Lilly, immunology, licensing, Lycia Therapeutics, pain, partnering, protein degradation 0 Comment

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal

Lilly taps Lycia for protein degrader tech in $1.6bn deal

https://pharmaphorum.com/news/lilly-taps-lycia-for-protein-degrader-tech-in-1-6bn-deal/

Digital/ News/ News

Akili adds to ADHD gaming range with $37.5m TALi licensing deal

Phil Taylor Akili, attention deficit hyperactivity disorder, digital, digital health, digital therapeutics, licensing, TALi 0 Comment

Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit

Akili adds to ADHD gaming range with $37.5m TALi licensing deal

https://pharmaphorum.com/news/akili-adds-to-adhd-gaming-range-with-37m-tali-licensing-deal/

News/ News/ R&D

Amgen pays Kyowa $400m upfront for OX40 eczema drug

Phil Taylor Amgen, atopic dermatitis, dermatology, Dupixent, Kyowa Kirin, licensing, OX40, Regeneron, Sanofi 0 Comment

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim

Amgen pays Kyowa $400m upfront for OX40 eczema drug

https://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/

News/ News/ R&D

Biogen bolsters ischaemic stroke pipeline with thrombolytic from TMS

Phil Taylor Biogen, central nervous system, licensing, stroke, thrombolysis 0 Comment

Biogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance

Biogen bolsters ischaemic stroke pipeline with thrombolytic from TMS

https://pharmaphorum.com/news/biogen-bolsters-ischaemic-stroke-pipeline-with-thrombolytic-from-tms/

News/ News/ Oncology

Merck KGaA offloads failed MEK programme to startup Day One

Phil Taylor brain cancer, Day One Biopharmaceuticals, licensing, Merck KGaA, Oncology 0 Comment

US biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s

Merck KGaA offloads failed MEK programme to startup Day One

https://pharmaphorum.com/news/merck-kgaa-offloads-failed-mek-programme-to-startup-day-one/

News/ News/ R&D

Lilly adds to pain pipeline with Asahi Kasei licensing deal

Phil Taylor Asahi Kasei, Eli Lilly, licensing, Neuropathic pain, pain 0 Comment

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has

Lilly adds to pain pipeline with Asahi Kasei licensing deal

https://pharmaphorum.com/news/lilly-adds-to-pain-pipeline-with-asahi-kasei-licensing-deal/

Trending

licensing

Login